FDA approved Awiqli (insulin icodec-abae) 700 units/mL on March 27, 2026 — ~2 months ahead of the projected May 29 PDUFA. First and only once-weekly basal insulin for adults with type 2 diabetes, reducing basal injections from seven to one per week. Based on ONWARDS Phase 3a programme. Nationwide US launch expected 2H 2026.
About
Type 2 diabetes is a chronic condition where the body struggles to regulate blood sugar, leading to serious long-term complications like heart disease, kidney failure, and vision loss. Awiqli is a once-weekly basal insulin analog that delivers a steady, long-acting supply of insulin to help manage blood sugar levels. By reducing the required injections from daily to just once a week, this treatment could make consistent blood sugar control more manageable for people living with this disease.
